Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,138.80
(
0.00%
)
US TECH 100
26,373.60
(
0.27%
)
Dow Jones
49,141.93
(
0.00%
)
Brent Oil
108.10
(
3.53%
)
Bitcoin
77,125.20
(
1.02%
)
News Focus
News Focus
Post# of 257458
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122898
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Wednesday, 10/31/2018 9:42:34 AM

Wednesday, October 31, 2018 9:42:34 AM

Post# of 257458
ORTX IPOs 16.43M* ADSs @$14.00 (low end of expected range):

https://www.nasdaq.com/press-release/orchard-therapeutics-announces-pricing-of-initial-public-offering-20181030-01810

Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies.

Orchard's advanced portfolio of autologous ex vivo gene therapies targets serious and life-threatening rare diseases, initially primary immune deficiencies, neurometabolic disorders and hemoglobinopathies.

*Assuming exercise of underwriter’s option.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today